Sales Dependence on Johnson & Johnson Vision Care
First written in FY2016. 14 of 25 entries say "Restated". Latest entry: FY2026.
Tokyo Automatic Machinery Works moved to the "Worse" side of this theme in 2023, 3 years after the typical company in this theme (2020).
The whole theme swung hardest in 2025: 14 of 29 companies on the "Worse" side.
8 other companies' latest entry also says "Mitigated".
- FY2026MitigatedAnnual report
「Fiscal year ended March 2025 12,890 6,766 52.5 Fiscal year ended March 2026 9,692 2,375 24.5」
The proportion of sales to Johnson & Johnson Vision Inc. declined from 52.5% in the previous year to 24.5%. However, the company continues to state that the company's capital investment trends have a significant impact on its business. - FY2025MitigatedAnnual report
「Fiscal year ended March 2024 13,458 8,261 61.4 Fiscal year ended March 2025 12,890 6,766 52.5」
The proportion of sales to Johnson & Johnson Vision Inc. declined from 61.4% in the previous year to 52.5%. However, the company continues to state that the company's capital investment trends have a significant impact on its business. - FY2024WorsenedAnnual report
「Fiscal year ended March 2024 13,458 8,261 61.4」
The proportion of sales to Johnson & Johnson Vision Inc. increased from 59.7% in the previous year to 61.4%, further increasing the risk of sales concentration with a specific customer. - FY2023WorsenedAnnual report
「Fiscal year ended March 2023 13,306 7,938 59.7」
The proportion of sales to Johnson & Johnson Vision Inc. increased from 46.4% in the previous fiscal year to 59.7%, further increasing the risk of sales concentration with a specific customer. - FY2022MitigatedAnnual report
「Fiscal year ended March 2022 8,819 4,090 46.4」
The proportion of sales to Johnson & Johnson Vision Inc. declined from 49.7% in the previous fiscal year to 46.4%. However, the company continues to state that sales concentration with a specific customer could affect operating results and financial position. - FY2022-Q3RestatedAnnual report
「During the cumulative third-quarter period, there were no new matters relating to the business or accounting information described in this quarterly report that could materially affect investment decisions, nor any material changes to the business and other risks described in the annual securities report for the preceding fiscal year.」
The company states that there have been no material changes in business and other risks, including its sales dependence on Johnson & Johnson Vision. - FY2022-Q1RestatedAnnual report
「During the cumulative first-quarter period, there were no new matters relating to the business or accounting information described in this quarterly report that could materially affect investment decisions, nor any material changes to the business and other risks described in the annual securities report for the preceding fiscal year.」
The company states that there have been no material changes in business and other risks, including its sales dependence on Johnson & Johnson Vision. - FY2021MitigatedAnnual report
「Fiscal year ended March 2021 10,708 5,322 49.7」
The proportion of sales to Johnson & Johnson Vision Inc. declined from 56.1% in the previous fiscal year to 49.7%. However, the company continues to state that its high sales proportion and trends in capital investment could affect operating results and other matters. - FY2021-Q3RestatedAnnual report
「During the cumulative third-quarter period, there were no new matters relating to the business or accounting information described in this quarterly report that could materially affect investment decisions, nor any material changes to the business and other risks described in the annual securities report for the preceding fiscal year.」
The company states that there have been no material changes in business and other risks, including its sales dependence on Johnson & Johnson Vision. - FY2021-Q2RestatedAnnual report
「During the cumulative second-quarter period, there were no new matters relating to the business or accounting information described in this quarterly report that could materially affect investment decisions, nor any material changes to the business and other risks described in the annual securities report for the preceding fiscal year.」
The company states that there have been no material changes in business and other risks, including its sales dependence on Johnson & Johnson Vision. - FY2021-Q1RestatedAnnual report
「During the cumulative first-quarter period, there were no new matters relating to the business or accounting information described in this quarterly report that could materially affect investment decisions, nor any material changes to the business and other risks described in the annual securities report for the preceding fiscal year.」
The company states that there have been no material changes in business and other risks, including its sales dependence on Johnson & Johnson Vision. - FY2020WorsenedAnnual report
「Fiscal year ended March 2020 12,337 6,920 56.1」
The proportion of sales to Johnson & Johnson Vision increased from 53.4% in the previous fiscal year to 56.1%, further increasing sales concentration risk. - FY2020-Q3RestatedAnnual report
「During the cumulative third-quarter period, there were no new matters relating to the business or accounting information described in this quarterly report that could materially affect investment decisions, nor any material changes to the business and other risks described in the annual securities report for the preceding fiscal year.」
The company states that there have been no material changes in business and other risks, including its sales dependence on Johnson & Johnson Vision Care. - FY2020-Q1RestatedAnnual report
「During the cumulative first-quarter period, there were no new matters relating to the business or accounting information described in this quarterly report that could materially affect investment decisions, nor any material changes to the business and other risks described in the annual securities report for the preceding fiscal year.」
The company states that there have been no material changes in business and other risks, including its sales dependence on Johnson & Johnson Vision Care. - FY2019WorsenedAnnual report
「A high proportion of the company's sales is generated from Johnson & Johnson Vision (U.S.), and changes in its sales trends could affect the company's operating results and other matters. Fiscal year ended March 2019 11,650 6,215 53.4」
The proportion of sales to the company increased from 24.1% in the previous fiscal year to 53.4%, increasing sales concentration risk. - FY2019-Q3RestatedAnnual report
「During the cumulative third-quarter period, there were no new matters relating to the business or accounting information described in this quarterly report that could materially affect investment decisions, nor any material changes to the business and other risks described in the annual securities report for the preceding fiscal year.」
The company states that there have been no material changes in business and other risks, including its sales dependence on Johnson & Johnson Vision Care. - FY2019-Q2RestatedAnnual report
「During the cumulative second-quarter period, there were no new matters relating to the business or accounting information described in this quarterly report that could materially affect investment decisions, nor any material changes to the business and other risks described in the annual securities report for the preceding fiscal year.」
The company states that there have been no material changes in business and other risks, including its sales dependence on Johnson & Johnson Vision Care. - FY2018MitigatedAnnual report
「Fiscal year ended March 2018 7,600 1,833 24.1」
The proportion of sales to Johnson & Johnson Vision declined from 29.1% in the previous fiscal year to 24.1%. However, the company continues to state that sales trends could affect operating results. - FY2018-Q2RestatedAnnual report
「During the cumulative second-quarter period, there were no new matters relating to the business or accounting information described in this quarterly report that could materially affect investment decisions, nor any material changes to the business and other risks described in the annual securities report for the preceding fiscal year.」
The company states that there have been no material changes in business and other risks, including its sales dependence on Johnson & Johnson Vision Care. - FY2018-Q1RestatedAnnual report
「During the cumulative first-quarter period, there were no new matters relating to the business or accounting information described in this quarterly report that could materially affect investment decisions, nor any material changes to the business and other risks described in the annual securities report for the preceding fiscal year.」
The company states that there have been no material changes in business and other risks, including its sales dependence on Johnson & Johnson Vision Care. - FY2017MitigatedAnnual report
「A high proportion of the company's sales is generated from Johnson & Johnson Vision Care (U.S.), and changes in its sales trends could affect the company's operating results and other matters. Fiscal year ended March 2017 7,567 2,200 29.1」
The proportion of sales to the company declined from 38.0% in the previous fiscal year to 29.1%. However, the company continues to state that its sales trends could affect operating results. - FY2017-Q3RestatedAnnual report
「During the cumulative third-quarter period, there were no new matters relating to the business or accounting information described in this quarterly report that could materially affect investment decisions, nor any material changes to the business and other risks described in the annual securities report for the preceding fiscal year.」
The company states that there have been no material changes in business and other risks, including its sales dependence on Johnson & Johnson Vision Care. - FY2017-Q2RestatedAnnual report
「During the cumulative second-quarter period, there were no new matters relating to the business or accounting information described in this quarterly report that could materially affect investment decisions, nor any material changes to the business and other risks described in the annual securities report for the preceding fiscal year.」
The company states that there have been no material changes in business and other risks, including its sales dependence on Johnson & Johnson Vision Care. - FY2017-Q1RestatedAnnual report
「During the cumulative first-quarter period, there were no new matters relating to the business or accounting information described in this quarterly report that could materially affect investment decisions, nor any material changes to the business and other risks described in the annual securities report for the preceding fiscal year.」
The company states that there have been no material changes in business and other risks, including its sales dependence on Johnson & Johnson Vision Care. - FY2016First statedAnnual report
「A high proportion of the company's sales is generated from Johnson & Johnson Vision Care (U.S.), and changes in its sales trends could affect the company's operating results and other matters.」
Sales to the company totaled ¥3,420.998 million for the fiscal year, accounting for 38.0% of total sales. The company explicitly identifies its high sales concentration as a risk.